IMUX

7.0654.40%
GW

Glenn Whaley

Chief Financial Officer

Mr. Glenn Whaley, CPA serves as Chief Financial Officer at Immunic, Inc. since March 2022. He served as Principal Financial and Accounting Officer at Immunic, Inc. since April 2020 until March 2022 and also served as it's Vice President of Finance since April 17, 2020 until March 2022. Mr. Whaley joined Immunic, Inc. since December 2019. Mr. Whaley served as its Principal Accounting Officer and Controller until April 17, 2020. Mr. Whaley served as a Principal Financial of Pernix Therapeutics Holdings, Inc since November 23, 2018 until May 15, 2019 and has served as its Principal Accounting Officer since May 22, 2018 until May 15, 2019 and served as its Interim Principal Accounting Officer since November 29, 2017 until May 22, 2018. Mr. Whaley has served as Vice President of Finance of Pernix Therapeutics Holdings, Inc. since November 29, 2017 and served as its Corporate Controller from November 29, 2017 to May 15, 2019. He joined Pernix Therapeutics in March 2015 as Vice President of Financial Planning & Analysis. Prior to Pernix Therapeutics, he served as Vice President of Finance for Alvogen, Inc. from May 2011 to March 2015. His responsibilities included serving as Vice President of Finance of U.S. Operations from August 2013 to March 2015 and Global Corporate Controller from May 2011 to August 2013. Prior to Alvogen, Mr. Whaley served as Corporate Controller of ImClone Systems Incorporated from January 2007 to May 2011 and served as Senior Director of Financial Reporting from January 2005 to December 2006. Prior to ImClone, Mr. Whaley served in a variety of financial roles at increasing levels of responsibility in public accounting and the pharmaceutical and telecommunications industries. Mr. Whaley is a member of the New Jersey Society of Certified Public Accountants and the American Institute of Certified Public Accountants. Mr. Whaley holds a Bachelor of Science degree from Rutgers University Business School.

Positions